MedTrace Logo

Nabilone and THC/CBD for the Treatment of FBSS Refractory Pain

NCT03210766 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2019-01-16

No results posted yet for this study

Summary

The aim of this study is to evaluate the efficacy of oral administration of nabilone or THC/CBD administration in combination with spinal cord stimulation (SCS) in FBSS patients refractory to other available therapeutic strategies.

Conditions

  • FBSS

Interventions

DRUG

Nabilone

DRUG

THC/CBD

Sponsors & Collaborators

  • Azienda Ospedaliera Universitaria Policlinico "G. Martino"

    lead OTHER

Principal Investigators

  • Domenico Quattrone, MD · S. Vincenzo Hospital ASP Messina

Eligibility

Min Age
45 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-01
Primary Completion
2015-01-01
Completion
2016-01-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03210766 on ClinicalTrials.gov